Diabetes Mellitus, Latent Tuberculosis
Conditions
Keywords
Treatment, Latent infection, Tuberculosis, Interferon gamma
Brief summary
Clinical test (essay) randomized to evaluate the toxicity adherence and efficiency of the chemoprophylaxis of tuberculosis (TB) in subjects with Diabetes Mellitus (DM) and latent TB. (600 subjects followed(continued) by 15 months). 3rd stage. Patients with DM and TB will be included to determine if the strict control of the dm achieved in clinics of the first level of attention improves clinical manifestations of tb, the result of treatment, the frequency of relapses, the mortality and the transmission to contacts. Elispot will be used to measure TB development and the time for the bacteriological negativization and biochemical parameters as well as tuberculin skin test (TST), quantiferon, in contacts. (160 patients 600 contacts followed(continued) for 12 months). additional there will be evaluated the socioeconomic impact of both diseases and his(her) control. 1er year: transverse study and recruitment years 2 and 3 participants' follow-ups in clinical tests(essays).
Interventions
DRUGIsoniazid 300Mg Tab
-TST tests will receive isoniazid 300Mg Tab for 6 months
DRUGIsoniazid 300 MG
\+ TST test will receive isoniazid 300MG Tab for 6 months
Sponsors
Instituto Nacional de Salud Publica, Mexico
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Positive HIV TST tuberculin
Exclusion criteria
* Previous TB treatment Hepatic failure AIDS
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Development of active TB | 6 months | Researchers will test patients at day 0 and day 180 of treatment to detect the development of active TB |
Outcome results
None listed